Related Experiment Video
Updated: Apr 8, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Application of Adaptive DP-optimality to Design a Pilot Study for a Clotting Time Test for Enoxaparin
Abhishek Gulati1,2, James M Faed3, Geoffrey K Isbister4
1Division of Clinical Pharmacology, Indiana University School of Medicine, R2 Building, 950 West Walnut Avenue, 4th Floor, Room E471, Indianapolis, Indiana, 46202, USA. agulati@iu.edu.
Purpose:
Dosing of enoxaparin, like other anticoagulants, may result in bleeding following excessive doses and clot formation if the dose is too low. We recently showed that a factor Xa based clotting time test could potentially assess the effect of enoxaparin on the clotting system. However, the test did not perform well in subsequent individuals and effectiveness of an exogenous phospholipid, Actin FS, in reducing the variability in the clotting time was assessed. The aim of this work was to conduct an adaptive pilot study to determine the range of concentrations of Xa and Actin FS to take forward into a proof-of-concept study.
Methods:
A nonlinear parametric function was developed to describe the response surface over the factors of interest. An adaptive method was used to estimate the parameters using a D-optimal design criterion. In order to provide a reasonable probability of observing a success of the clotting time test, a P-optimal design criterion was incorporated using a loss function to describe the hybrid DP-optimality.
Results:
The use of adaptive DP-optimality method resulted in an efficient estimation of model parameters using data from only 6 healthy volunteers. The use of response surface modelling identified a range of sets of Xa and Actin FS concentrations, any of which could be used for the proof-of-concept study.
Conclusions:
This study shows that parsimonious adaptive DP-optimal designs may provide both precise parameter estimates for response surface modelling as well as clinical confidence in the potential benefits of the study.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Venous Thrombosis III: Interprofessional Care
Bioavailability Study Design: Healthy Subjects Versus Patients
Methods of Medium Optimization
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.

